Clinical Utility and Safety of a Model-Based Patient-Tailored Dose of Vancomycin in Neonates

Antimicrobial Agents and Chemotherapy
Stéphanie LerouxWei Zhao

Abstract

Pharmacokinetic modeling has often been applied to evaluate vancomycin pharmacokinetics in neonates. However, clinical application of the model-based personalized vancomycin therapy is still limited. The objective of the present study was to evaluate the clinical utility and safety of a model-based patient-tailored dose of vancomycin in neonates. A model-based vancomycin dosing calculator, developed from a population pharmacokinetic study, has been integrated into the routine clinical care in 3 neonatal intensive care units (Robert Debré, Cochin Port Royal, and Clocheville hospitals) between 2012 and 2014. The target attainment rate, defined as the percentage of patients with a first therapeutic drug monitoring serum vancomycin concentration achieving the target window of 15 to 25 mg/liter, was selected as an endpoint for evaluating the clinical utility. The safety evaluation was focused on nephrotoxicity. The clinical application of the model-based patient-tailored dose of vancomycin has been demonstrated in 190 neonates. The mean (standard deviation) gestational and postnatal ages of the study population were 31.1 (4.9) weeks and 16.7 (21.7) days, respectively. The target attainment rate increased from 41% to 72% without any ...Continue Reading

References

May 9, 2000·Clinical Pharmacology and Therapeutics·M de HoogJ N van den Anker
Sep 19, 2003·The New England Journal of Medicine·Gregory L KearnsRalph E Kauffman
May 14, 2004·Clinical Pharmacokinetics·Matthijs de HoogJohn N van den Anker
Jan 19, 2005·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Imad R MakhoulUNKNOWN Israel Neonatal Network
Jun 10, 2010·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Luregn J SchlapbachChristoph Aebi
Dec 25, 2010·The American Journal of Medicine·Lindsey PritchardK Bruce Bayley
Mar 14, 2012·European Journal of Clinical Pharmacology·Sepideh ElyasiAmirhooshang Mohammadpour
Apr 17, 2012·International Journal of Pharmaceutics·Anne SmitsKarel Allegaert
Nov 10, 2012·Seminars in Fetal & Neonatal Medicine·Evelyne Jacqz-AigrainJohn N van den Anker
Nov 28, 2012·Clinical Pharmacokinetics·Amélie MarsotNicolas Simon
Dec 21, 2012·Archives of Disease in Childhood·Wei ZhaoEvelyne Jacqz-Aigrain
Aug 16, 2014·World Journal of Pediatrics : WJP·Wei ZhaoEvelyne Jacqz-Aigrain
May 16, 2015·Clinical Pharmacology and Therapeutics·J WangG J Burckart
Aug 21, 2015·Expert Review of Clinical Pharmacology·Evelyne Jacqz-AigrainMike Sharland

❮ Previous
Next ❯

Citations

Oct 31, 2017·Therapeutic Drug Monitoring·Tõnis TasaIrja Lutsar
Aug 30, 2018·Pharmacology Research & Perspectives·Joaquim F MonteiroPaula Fresco
Sep 12, 2018·Journal of Clinical Pharmacology·Joshua C EuteneuerHenry T Akinbi
Sep 7, 2017·Clinical and Translational Science·Daniel GonzalezJ Robert Powell
Oct 27, 2017·Child's Nervous System : ChNS : Official Journal of the International Society for Pediatric Neurosurgery·Jaya Madhura ParasuramanAxel Heep
May 11, 2018·Acta Clinica Belgica·Karel Allegaert, John van den Anker
May 30, 2019·Frontiers in Pediatrics·Manon TauzinLaurence Caeymaex
Jan 21, 2021·International Journal of Environmental Research and Public Health·Tamara van DongeKarel Allegaert
Mar 13, 2021·Frontiers in Pediatrics·Alan AbdullaMatthijs de Hoog
Apr 4, 2021·Antibiotics·Marta Mejías-TruebaMaria Victoria Gil-Navarro
Jul 28, 2021·Expert Review of Clinical Pharmacology·Quyen TuJason A Roberts

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Archives of Disease in Childhood. Fetal and Neonatal Edition
C Grimsley, A H Thomson
Clinical Pharmacology and Therapeutics
R E SeayB E Edgren
Clinical Pharmacology and Therapeutics
Matthijs de HoogJohn N van den Anker
© 2021 Meta ULC. All rights reserved